19 October 2022 - The MSAC Secretariat has published a list of applications scheduled to be considered by the ESC on 9 -10 February 2023.

The agenda currently has 13 items. Applications of note include:

• 1658.1 - Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib
• 1703 – Detection of measurable residual disease in patients with acute lymphoblastic leukaemia
• 1714 – National Blood Authority listing for susoctocog alfa for treatment of bleeding episodes with acquired haemophilia A
• 1722 – Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
• 1726 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS niraparib

Read ESC agenda